{"id":746577,"date":"2023-04-11T08:29:11","date_gmt":"2023-04-11T12:29:11","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/guardant-health-to-present-data-from-14-studies-highlighting-advances-in-precision-oncology-and-cancer-screening-at-2023-aacr-annual-meeting\/"},"modified":"2023-04-11T08:29:11","modified_gmt":"2023-04-11T12:29:11","slug":"guardant-health-to-present-data-from-14-studies-highlighting-advances-in-precision-oncology-and-cancer-screening-at-2023-aacr-annual-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/guardant-health-to-present-data-from-14-studies-highlighting-advances-in-precision-oncology-and-cancer-screening-at-2023-aacr-annual-meeting\/","title":{"rendered":"Guardant Health to Present Data From 14 Studies Highlighting Advances in Precision Oncology and Cancer Screening at 2023 AACR Annual Meeting"},"content":{"rendered":"<p>        <!--.bwalignl { text-align: left }\n.bwblockalignl { margin-left: 0px; margin-right: auto }\n.bwcellpmargin { margin-bottom: 0px; margin-top: 0px }\n.bwlistdisc { list-style-type: disc }\n.bwpadl0 { padding-left: 0px }\n.bwpadr0 { padding-right: 0px }\n.bwtablemarginb { margin-bottom: 10px }\n.bwvertalignt { vertical-align: top }\n.bwwidth1 { width: 1% }\n.bwwidth100 { width: 100% }\n.bwwidth29 { width: 29% }\n.bwwidth4 { width: 4% }\n.bwwidth5 { width: 5% }\n.bwwidth59 { width: 59% }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p><b>Guardant Health to Present Data From 14 Studies Highlighting Advances in Precision Oncology and Cancer Screening at 2023 AACR Annual Meeting<\/b><\/p>\n<p><i>New research demonstrates value of epigenomic analysis and methylation sequencing capabilities of GuardantINFINITY\u2122 platform for biomarker discovery, therapy selection and response monitoring<\/i><\/p>\n<p>PALO ALTO, Calif.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nGuardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that it will present data from 14 studies highlighting advances in precision oncology and cancer screening at the 2023 American Association for Cancer Research (AACR) Annual Meeting, April 14-19 in Orlando, Florida.<\/p>\n<p>\n\u201cWe look forward to sharing new data at AACR, in particular research demonstrating the tremendous possibilities of epigenomic analysis in biomarker discovery and cancer care,\u201d said Helmy Eltoukhy, Guardant Health chairman and co-CEO. \u201cThese presentations show how gaining deeper insights into the tumor microenvironment can help us identify new potential biomarker targets for therapy and predictive markers for treatment resistance, quantify circulating tumor DNA, and contribute to better-informed patient care.\u201d<\/p>\n<p>\nMultiple studies to be presented at the meeting highlight the new GuardantINFINITY sequencing platform and demonstrate the utility of its methylation sequencing and epigenomic analysis capabilities in biomarker discovery, therapy selection and response monitoring. In particular, studies show that:<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nMethylome sequencing with a liquid-only approach using the GuardantINFINITY platform can quantify circulating tumor DNA level and change with greater sensitivity and precision than genomic sequencing, making longitudinal ctDNA monitoring accessible to a broader range of patients. (Abstract 3123)<\/p>\n<\/li>\n<li>\nCancer genomics alone provides little information on tumor phenotype or functional state, which are governed by epigenetic mechanisms, notably methylation of regulatory regions. The analytical validation of the GuardantINFINITY genomic and epigenomic liquid biopsy platform showed its potential for ultra-sensitive ctDNA detection for minimal residual disease and recurrence surveillance, tumor fraction quantitation for therapy monitoring, oncogenic virus detection, immunogenotyping, epigenotyping, and tumor phenotype characterization, representing a new standard in biomarker discovery. (Abstract 6601)<\/p>\n<\/li>\n<\/ul>\n<p><b>Full List of Guardant Health Presentations<\/b><\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl bwwidth100\">\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwwidth5\" rowspan=\"1\" colspan=\"1\"><b>Abstract<\/b><\/td>\n<td class=\"bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<td class=\"bwvertalignt bwpadl0 bwwidth4\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><b>Poster<\/b><\/p>\n<\/td>\n<td class=\"bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<td class=\"bwvertalignt bwpadl0 bwwidth59\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><b>Title<\/b><\/p>\n<\/td>\n<td class=\"bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<td class=\"bwvertalignt bwpadl0 bwwidth29\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><b>Product<\/b><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwwidth5\" rowspan=\"1\" colspan=\"1\" \/>\n<td class=\"bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<td class=\"bwpadl0 bwwidth4\" rowspan=\"1\" colspan=\"1\" \/>\n<td class=\"bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<td class=\"bwpadl0 bwwidth59\" rowspan=\"1\" colspan=\"1\" \/>\n<td class=\"bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<td class=\"bwpadl0 bwwidth29\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0\" colspan=\"7\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><i>Sunday, April 16 | 1:30 \u2013 5:00 pm<\/i><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwpadr0 bwalignl bwvertalignt bwwidth5\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n1052<\/p>\n<\/td>\n<td class=\"bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<td class=\"bwpadr0 bwalignl bwvertalignt bwpadl0 bwwidth4\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n29<\/p>\n<\/td>\n<td class=\"bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<td class=\"bwvertalignt bwalignl bwpadl0 bwwidth59\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\nBackground variability in plasma ctDNA levels in patients with advanced lung cancer in the absence of treatment<\/p>\n<\/td>\n<td class=\"bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<td class=\"bwvertalignt bwalignl bwpadl0 bwwidth29\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\nGuardant360\u00ae<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwwidth5\" rowspan=\"1\" colspan=\"1\" \/>\n<td class=\"bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<td class=\"bwpadl0 bwwidth4\" rowspan=\"1\" colspan=\"1\" \/>\n<td class=\"bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<td class=\"bwpadl0 bwwidth59\" rowspan=\"1\" colspan=\"1\" \/>\n<td class=\"bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<td class=\"bwpadl0 bwwidth29\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0\" colspan=\"7\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><i>Monday, April 17 | 9:00 am \u2013 12:30 pm<\/i><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwalignl bwwidth5\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\nLB123<\/p>\n<\/td>\n<td class=\"bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<td class=\"bwpadr0 bwalignl bwvertalignt bwpadl0 bwwidth4\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n6<\/p>\n<\/td>\n<td class=\"bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<td class=\"bwvertalignt bwalignl bwpadl0 bwwidth59\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\nPoorer outcomes in <i>EGFR<\/i> L858R-driven NSCLC treated with osimertinib may be addressed with novel combination of BLU-945 and osimertinib<\/p>\n<\/td>\n<td class=\"bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<td class=\"bwvertalignt bwalignl bwpadl0 bwwidth29\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\nGuardantINFORM\u2122<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwwidth5\" rowspan=\"1\" colspan=\"1\" \/>\n<td class=\"bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<td class=\"bwpadl0 bwwidth4\" rowspan=\"1\" colspan=\"1\" \/>\n<td class=\"bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<td class=\"bwpadl0 bwwidth59\" rowspan=\"1\" colspan=\"1\" \/>\n<td class=\"bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<td class=\"bwpadl0 bwwidth29\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0\" colspan=\"7\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><i>Monday, April 17 | 1:30 \u2013 5:00 pm<\/i><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwpadr0 bwalignl bwvertalignt bwwidth5\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n3331<\/p>\n<\/td>\n<td class=\"bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<td class=\"bwpadr0 bwalignl bwvertalignt bwpadl0 bwwidth4\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n6<\/p>\n<\/td>\n<td class=\"bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<td class=\"bwvertalignt bwalignl bwpadl0 bwwidth59\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\nHighly sensitive blood-based multi-cancer screening device with tiered specificity based on diagnostic workflow<\/p>\n<\/td>\n<td class=\"bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<td class=\"bwvertalignt bwalignl bwpadl0 bwwidth29\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\nShield\u2122<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwpadr0 bwalignl bwvertalignt bwwidth5\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n3123<\/p>\n<\/td>\n<td class=\"bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<td class=\"bwpadr0 bwalignl bwvertalignt bwpadl0 bwwidth4\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n9<\/p>\n<\/td>\n<td class=\"bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<td class=\"bwvertalignt bwalignl bwpadl0 bwwidth59\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\nA method for quantifying circulating tumor DNA level and molecular response using methylome sequencing<\/p>\n<\/td>\n<td class=\"bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<td class=\"bwvertalignt bwalignl bwpadl0 bwwidth29\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\nGuardantINFINITY<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwpadr0 bwalignl bwvertalignt bwwidth5\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n3128<\/p>\n<\/td>\n<td class=\"bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<td class=\"bwpadr0 bwalignl bwvertalignt bwpadl0 bwwidth4\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n14<\/p>\n<\/td>\n<td class=\"bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<td class=\"bwvertalignt bwalignl bwpadl0 bwwidth59\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\nUsing Kmerizer, a germline and somatic genotyper for immune associated complex alleles in GuardantINFINITY, for immunotherapy response prediction using cfDNA<\/p>\n<\/td>\n<td class=\"bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<td class=\"bwvertalignt bwalignl bwpadl0 bwwidth29\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\nGuardantINFINITY<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwpadr0 bwalignl bwvertalignt bwwidth5\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n3125<\/p>\n<\/td>\n<td class=\"bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<td class=\"bwpadr0 bwalignl bwvertalignt bwpadl0 bwwidth4\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n21<\/p>\n<\/td>\n<td class=\"bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<td class=\"bwvertalignt bwalignl bwpadl0 bwwidth59\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\nValidation of a bioinformatic model for classifying non-tumor variants in a cell-free DNA liquid biopsy assay<\/p>\n<\/td>\n<td class=\"bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<td class=\"bwvertalignt bwalignl bwpadl0 bwwidth29\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\nGuardantINFINITY<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwwidth5\" rowspan=\"1\" colspan=\"1\" \/>\n<td class=\"bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<td class=\"bwpadl0 bwwidth4\" rowspan=\"1\" colspan=\"1\" \/>\n<td class=\"bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<td class=\"bwpadl0 bwwidth59\" rowspan=\"1\" colspan=\"1\" \/>\n<td class=\"bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<td class=\"bwpadl0 bwwidth29\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0\" colspan=\"7\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><i>Tuesday, April 18 | 1:30 \u2013 5:00 pm<\/i><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwpadr0 bwalignl bwvertalignt bwwidth5\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n5573<\/p>\n<\/td>\n<td class=\"bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<td class=\"bwpadr0 bwalignl bwvertalignt bwpadl0 bwwidth4\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n30<\/p>\n<\/td>\n<td class=\"bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<td class=\"bwvertalignt bwalignl bwpadl0 bwwidth59\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\nUse of circulating tumor DNA (ctDNA) for early assessment of treatment response in patients with non-small cell lung cancer (NSCLC): A real-world (RW) analysis incorporating baseline ctDNA level and molecular response<\/p>\n<\/td>\n<td class=\"bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<td class=\"bwvertalignt bwalignl bwpadl0 bwwidth29\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\nGuardantINFORM<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwpadr0 bwalignl bwvertalignt bwwidth5\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n4264<\/p>\n<\/td>\n<td class=\"bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<td class=\"bwpadr0 bwalignl bwvertalignt bwpadl0 bwwidth4\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n13<\/p>\n<\/td>\n<td class=\"bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<td class=\"bwvertalignt bwalignl bwpadl0 bwwidth59\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\nThe genomic landscape of <i>RET<\/i> fusions in non-small cell lung cancer and the impact of co-occurring genomic alterations on the efficacy of selective RET inhibitors<\/p>\n<\/td>\n<td class=\"bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<td class=\"bwvertalignt bwalignl bwpadl0 bwwidth29\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\nGuardant360<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwalignl bwwidth5\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\nCT278<\/p>\n<\/td>\n<td class=\"bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<td class=\"bwpadr0 bwalignl bwvertalignt bwpadl0 bwwidth4\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n18<\/p>\n<\/td>\n<td class=\"bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<td class=\"bwvertalignt bwalignl bwpadl0 bwwidth59\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\"><i>ERBB2<\/i> amplification detected in ctDNA as a surrogate for tumor tissue FISH analysis of HER2 status in a phase 1 study with zanidatamab for the treatment of locally advanced or metastatic HER2 expressing cancers<\/p>\n<\/td>\n<td class=\"bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<td class=\"bwvertalignt bwalignl bwpadl0 bwwidth29\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\nGuardant360<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwwidth5\" rowspan=\"1\" colspan=\"1\" \/>\n<td class=\"bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<td class=\"bwpadl0 bwwidth4\" rowspan=\"1\" colspan=\"1\" \/>\n<td class=\"bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<td class=\"bwpadl0 bwwidth59\" rowspan=\"1\" colspan=\"1\" \/>\n<td class=\"bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<td class=\"bwpadl0 bwwidth29\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0\" colspan=\"7\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><i>Wednesday, April 19 | 9:00 am \u2013 12:30 pm<\/i><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwpadr0 bwalignl bwvertalignt bwwidth5\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n6087<\/p>\n<\/td>\n<td class=\"bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<td class=\"bwpadr0 bwalignl bwvertalignt bwpadl0 bwwidth4\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n27<\/p>\n<\/td>\n<td class=\"bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<td class=\"bwvertalignt bwalignl bwpadl0 bwwidth59\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\nMutation and co-mutation landscape of <i>ERBB2<\/i> alterations in advanced NSCLC<\/p>\n<\/td>\n<td class=\"bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<td class=\"bwvertalignt bwalignl bwpadl0 bwwidth29\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\nGuardant360<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwpadr0 bwalignl bwvertalignt bwwidth5\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n6744<\/p>\n<\/td>\n<td class=\"bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<td class=\"bwpadr0 bwalignl bwvertalignt bwpadl0 bwwidth4\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n4<\/p>\n<\/td>\n<td class=\"bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<td class=\"bwvertalignt bwalignl bwpadl0 bwwidth59\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\nCell-free DNA detection of alterations in the MAPK pathway in metastatic hormone receptor positive breast cancer: a multi-institutional analysis of incidence and clinical outcomes<\/p>\n<\/td>\n<td class=\"bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<td class=\"bwvertalignt bwalignl bwpadl0 bwwidth29\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\nGuardant360<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwpadr0 bwalignl bwvertalignt bwwidth5\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n6094<\/p>\n<\/td>\n<td class=\"bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<td class=\"bwpadr0 bwalignl bwvertalignt bwpadl0 bwwidth4\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n2<\/p>\n<\/td>\n<td class=\"bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<td class=\"bwvertalignt bwalignl bwpadl0 bwwidth59\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\nLongitudinal analysis of PARP inhibitor and platinum resistance in <i>BRCA1\/2<\/i>m breast cancer using liquid biopsy<\/p>\n<\/td>\n<td class=\"bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<td class=\"bwvertalignt bwalignl bwpadl0 bwwidth29\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\nGuardantINFINITY<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwpadr0 bwalignl bwvertalignt bwwidth5\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n6601<\/p>\n<\/td>\n<td class=\"bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<td class=\"bwpadr0 bwalignl bwvertalignt bwpadl0 bwwidth4\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n6<\/p>\n<\/td>\n<td class=\"bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<td class=\"bwvertalignt bwalignl bwpadl0 bwwidth59\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\nAnalytical validation of a robust integrated genomic and epigenomic liquid biopsy for biomarker discovery, therapy selection, and response monitoring<\/p>\n<\/td>\n<td class=\"bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<td class=\"bwvertalignt bwalignl bwpadl0 bwwidth29\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\nGuardantINFINITY<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwpadr0 bwalignl bwvertalignt bwwidth5\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n6603<\/p>\n<\/td>\n<td class=\"bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<td class=\"bwpadr0 bwalignl bwvertalignt bwpadl0 bwwidth4\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n8<\/p>\n<\/td>\n<td class=\"bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<td class=\"bwvertalignt bwalignl bwpadl0 bwwidth59\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\"><i>BRCA1<\/i> promoter methylation in sporadic breast cancer patients detected by liquid biopsy<\/p>\n<\/td>\n<td class=\"bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<td class=\"bwvertalignt bwalignl bwpadl0 bwwidth29\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\nGuardantINFINITY<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p>\nThe full abstracts for Guardant Health and a list of all abstracts being presented at the meeting can be found at the AACR website <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.aacr.org%2Fmeeting%2Faacr-annual-meeting-2023%2Fabstracts%2F&amp;esheet=53378868&amp;newsitemid=20230411005247&amp;lan=en-US&amp;anchor=here&amp;index=1&amp;md5=d84dac0a821346f724c8d9086d865fa1\">here<\/a>.<\/p>\n<p>\nFor more information and updates from the meeting, follow Guardant Health on <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fguardanthealth&amp;esheet=53378868&amp;newsitemid=20230411005247&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=2&amp;md5=d42a1222f05c8f58238e990b6a050932\">LinkedIn<\/a> and <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FGuardantHealth&amp;esheet=53378868&amp;newsitemid=20230411005247&amp;lan=en-US&amp;anchor=Twitter&amp;index=3&amp;md5=2ceef9704e374324062e7061b1486506\">Twitter<\/a> or visit AACR booth #2465.<\/p>\n<p><b>About Guardant Health<\/b><\/p>\n<p>\nGuardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched Guardant360<sup>\u00ae<\/sup>, Guardant360<sup>\u00ae<\/sup> CDx, Guardant360 TissueNext\u2122, Guardant360 Response\u2122, and GuardantINFINITY\u2122 tests for advanced-stage cancer patients, and Guardant Reveal\u2122 for early-stage cancer patients. The Guardant Health screening portfolio, including the commercially launched Shield\u2122 test, aims to address the needs of individuals eligible for cancer screening. For more information, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fguardanthealth.com%2F&amp;esheet=53378868&amp;newsitemid=20230411005247&amp;lan=en-US&amp;anchor=guardanthealth.com&amp;index=4&amp;md5=846c590dd6d62fcec32dd92f7225cdc8\">guardanthealth.com<\/a> and follow the company on <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fguardanthealth&amp;esheet=53378868&amp;newsitemid=20230411005247&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=5&amp;md5=ac4740e32d8fb00c6685717df9f872cf\">LinkedIn<\/a> and <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FGuardantHealth&amp;esheet=53378868&amp;newsitemid=20230411005247&amp;lan=en-US&amp;anchor=Twitter&amp;index=6&amp;md5=a69fcd772793bed4662dadae826abc5f\">Twitter<\/a>.<\/p>\n<p><b>Forward-Looking Statements<\/b><\/p>\n<p>\nThis press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health\u2019s liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health\u2019s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions \u201cRisk Factors\u201d and \u201cManagement\u2019s Discussion and Analysis of Financial Condition and Results of Operation\u201d and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2022, and in its other reports filed with or furnished to the Securities and Exchange Commission thereafter. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health\u2019s views as of any date subsequent to the date of this press release.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230411005247r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20230411005247\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20230411005247\/en\/<\/a><\/span><\/p>\n<p><b>Investor Contact:<br \/>\n<\/b><br \/>Alex Kleban<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:investors@guardanthealth.com\">investors@guardanthealth.com<br \/>\n<\/a><br \/>+1 657-254-5417<\/p>\n<p><b>Media Contact:<br \/>\n<\/b><br \/>Michael Weist<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:press@guardanthealth.com\">press@guardanthealth.com<br \/>\n<\/a><br \/>+1 317-371-0035<\/p>\n<p><b>KEYWORDS:<\/b> California Florida United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Oncology Health Genetics Clinical Trials Research Science Biotechnology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230411005247\/en\/1330243\/3\/GuardantHealthLogo_TM_RGB-2C.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Guardant Health to Present Data From 14 Studies Highlighting Advances in Precision Oncology and Cancer Screening at 2023 AACR Annual Meeting New research demonstrates value of epigenomic analysis and methylation sequencing capabilities of GuardantINFINITY\u2122 platform for biomarker discovery, therapy selection and response monitoring PALO ALTO, Calif.&#8211;(BUSINESS WIRE)&#8211; Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that it will present data from 14 studies highlighting advances in precision oncology and cancer screening at the 2023 American Association for Cancer Research (AACR) Annual Meeting, April 14-19 in Orlando, Florida. \u201cWe look forward to sharing new data at AACR, in particular research demonstrating the tremendous possibilities of epigenomic analysis in biomarker discovery and cancer care,\u201d said Helmy Eltoukhy, Guardant &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/guardant-health-to-present-data-from-14-studies-highlighting-advances-in-precision-oncology-and-cancer-screening-at-2023-aacr-annual-meeting\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Guardant Health to Present Data From 14 Studies Highlighting Advances in Precision Oncology and Cancer Screening at 2023 AACR Annual Meeting&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-746577","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Guardant Health to Present Data From 14 Studies Highlighting Advances in Precision Oncology and Cancer Screening at 2023 AACR Annual Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/guardant-health-to-present-data-from-14-studies-highlighting-advances-in-precision-oncology-and-cancer-screening-at-2023-aacr-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Guardant Health to Present Data From 14 Studies Highlighting Advances in Precision Oncology and Cancer Screening at 2023 AACR Annual Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Guardant Health to Present Data From 14 Studies Highlighting Advances in Precision Oncology and Cancer Screening at 2023 AACR Annual Meeting New research demonstrates value of epigenomic analysis and methylation sequencing capabilities of GuardantINFINITY\u2122 platform for biomarker discovery, therapy selection and response monitoring PALO ALTO, Calif.&#8211;(BUSINESS WIRE)&#8211; Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that it will present data from 14 studies highlighting advances in precision oncology and cancer screening at the 2023 American Association for Cancer Research (AACR) Annual Meeting, April 14-19 in Orlando, Florida. \u201cWe look forward to sharing new data at AACR, in particular research demonstrating the tremendous possibilities of epigenomic analysis in biomarker discovery and cancer care,\u201d said Helmy Eltoukhy, Guardant &hellip; Continue reading &quot;Guardant Health to Present Data From 14 Studies Highlighting Advances in Precision Oncology and Cancer Screening at 2023 AACR Annual Meeting&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/guardant-health-to-present-data-from-14-studies-highlighting-advances-in-precision-oncology-and-cancer-screening-at-2023-aacr-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-11T12:29:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230411005247r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/guardant-health-to-present-data-from-14-studies-highlighting-advances-in-precision-oncology-and-cancer-screening-at-2023-aacr-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/guardant-health-to-present-data-from-14-studies-highlighting-advances-in-precision-oncology-and-cancer-screening-at-2023-aacr-annual-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Guardant Health to Present Data From 14 Studies Highlighting Advances in Precision Oncology and Cancer Screening at 2023 AACR Annual Meeting\",\"datePublished\":\"2023-04-11T12:29:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/guardant-health-to-present-data-from-14-studies-highlighting-advances-in-precision-oncology-and-cancer-screening-at-2023-aacr-annual-meeting\\\/\"},\"wordCount\":1110,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/guardant-health-to-present-data-from-14-studies-highlighting-advances-in-precision-oncology-and-cancer-screening-at-2023-aacr-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230411005247r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/guardant-health-to-present-data-from-14-studies-highlighting-advances-in-precision-oncology-and-cancer-screening-at-2023-aacr-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/guardant-health-to-present-data-from-14-studies-highlighting-advances-in-precision-oncology-and-cancer-screening-at-2023-aacr-annual-meeting\\\/\",\"name\":\"Guardant Health to Present Data From 14 Studies Highlighting Advances in Precision Oncology and Cancer Screening at 2023 AACR Annual Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/guardant-health-to-present-data-from-14-studies-highlighting-advances-in-precision-oncology-and-cancer-screening-at-2023-aacr-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/guardant-health-to-present-data-from-14-studies-highlighting-advances-in-precision-oncology-and-cancer-screening-at-2023-aacr-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230411005247r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2023-04-11T12:29:11+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/guardant-health-to-present-data-from-14-studies-highlighting-advances-in-precision-oncology-and-cancer-screening-at-2023-aacr-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/guardant-health-to-present-data-from-14-studies-highlighting-advances-in-precision-oncology-and-cancer-screening-at-2023-aacr-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/guardant-health-to-present-data-from-14-studies-highlighting-advances-in-precision-oncology-and-cancer-screening-at-2023-aacr-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230411005247r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230411005247r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/guardant-health-to-present-data-from-14-studies-highlighting-advances-in-precision-oncology-and-cancer-screening-at-2023-aacr-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Guardant Health to Present Data From 14 Studies Highlighting Advances in Precision Oncology and Cancer Screening at 2023 AACR Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Guardant Health to Present Data From 14 Studies Highlighting Advances in Precision Oncology and Cancer Screening at 2023 AACR Annual Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/guardant-health-to-present-data-from-14-studies-highlighting-advances-in-precision-oncology-and-cancer-screening-at-2023-aacr-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Guardant Health to Present Data From 14 Studies Highlighting Advances in Precision Oncology and Cancer Screening at 2023 AACR Annual Meeting - Market Newsdesk","og_description":"Guardant Health to Present Data From 14 Studies Highlighting Advances in Precision Oncology and Cancer Screening at 2023 AACR Annual Meeting New research demonstrates value of epigenomic analysis and methylation sequencing capabilities of GuardantINFINITY\u2122 platform for biomarker discovery, therapy selection and response monitoring PALO ALTO, Calif.&#8211;(BUSINESS WIRE)&#8211; Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that it will present data from 14 studies highlighting advances in precision oncology and cancer screening at the 2023 American Association for Cancer Research (AACR) Annual Meeting, April 14-19 in Orlando, Florida. \u201cWe look forward to sharing new data at AACR, in particular research demonstrating the tremendous possibilities of epigenomic analysis in biomarker discovery and cancer care,\u201d said Helmy Eltoukhy, Guardant &hellip; Continue reading \"Guardant Health to Present Data From 14 Studies Highlighting Advances in Precision Oncology and Cancer Screening at 2023 AACR Annual Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/guardant-health-to-present-data-from-14-studies-highlighting-advances-in-precision-oncology-and-cancer-screening-at-2023-aacr-annual-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2023-04-11T12:29:11+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230411005247r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/guardant-health-to-present-data-from-14-studies-highlighting-advances-in-precision-oncology-and-cancer-screening-at-2023-aacr-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/guardant-health-to-present-data-from-14-studies-highlighting-advances-in-precision-oncology-and-cancer-screening-at-2023-aacr-annual-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Guardant Health to Present Data From 14 Studies Highlighting Advances in Precision Oncology and Cancer Screening at 2023 AACR Annual Meeting","datePublished":"2023-04-11T12:29:11+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/guardant-health-to-present-data-from-14-studies-highlighting-advances-in-precision-oncology-and-cancer-screening-at-2023-aacr-annual-meeting\/"},"wordCount":1110,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/guardant-health-to-present-data-from-14-studies-highlighting-advances-in-precision-oncology-and-cancer-screening-at-2023-aacr-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230411005247r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/guardant-health-to-present-data-from-14-studies-highlighting-advances-in-precision-oncology-and-cancer-screening-at-2023-aacr-annual-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/guardant-health-to-present-data-from-14-studies-highlighting-advances-in-precision-oncology-and-cancer-screening-at-2023-aacr-annual-meeting\/","name":"Guardant Health to Present Data From 14 Studies Highlighting Advances in Precision Oncology and Cancer Screening at 2023 AACR Annual Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/guardant-health-to-present-data-from-14-studies-highlighting-advances-in-precision-oncology-and-cancer-screening-at-2023-aacr-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/guardant-health-to-present-data-from-14-studies-highlighting-advances-in-precision-oncology-and-cancer-screening-at-2023-aacr-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230411005247r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2023-04-11T12:29:11+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/guardant-health-to-present-data-from-14-studies-highlighting-advances-in-precision-oncology-and-cancer-screening-at-2023-aacr-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/guardant-health-to-present-data-from-14-studies-highlighting-advances-in-precision-oncology-and-cancer-screening-at-2023-aacr-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/guardant-health-to-present-data-from-14-studies-highlighting-advances-in-precision-oncology-and-cancer-screening-at-2023-aacr-annual-meeting\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230411005247r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230411005247r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/guardant-health-to-present-data-from-14-studies-highlighting-advances-in-precision-oncology-and-cancer-screening-at-2023-aacr-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Guardant Health to Present Data From 14 Studies Highlighting Advances in Precision Oncology and Cancer Screening at 2023 AACR Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/746577","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=746577"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/746577\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=746577"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=746577"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=746577"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}